Dr. Adarsh Shetty, General Manager - Medical Affairs of Gufic said, “Looking at the convincing results, we are optimistic that Immunocin α can become an important drug amongst the global efforts to fight the COVID-19 pandemic and will add to Gufic's unique legacy of bringing forward breakthroughs in infectious diseases when they are needed most. Gufic has been relentlessly committed to saving and improving lives. We will continue to work with regulatory agencies on our applications and do everything we can to bring novel molecules to patients as quickly as possible.”

Thymosin α 1 (Immunocin α) is an endogenous polypeptide hormone secreted by thymic epithelial cells. As an immunomodulatory therapy, Thymosin α 1 has been investigated in many diseases involving immune dysfunction (such as sepsis, cystic fibrosis, and hepatitis viral infection) and is associated with an improved patient outcome. Thymosin α 1 increase T cell numbers by promoting T cell development and proliferation, enhance their function and prevents & corrects lymphopaenia.

Gufic is engaged in the research and development, manufacturing, marketing, distribution and sale of pharmaceutical and allied products. The pharmaceutical company's net profit advanced 36% to Rs 21.03 crore on 3.3% increase in net sales to Rs 172.07 crore in Q3 FY22 over Q3 FY21.